The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Shchulkin A.V.

Ryazan State Medical University

Chernykh I.V.

Ryazan State Medical University

Abalenikhina Y.V.

Ryazan State Medical University

Gatsanoga M.V.

Ryazan State Medical University

Gradinar M.M.

Ryazan State Medical University

Ananyeva P.D.

Ryazan State Medical University

Yakusheva E.N.

Ryazan State Medical University

Study of drug-drug interactions between Mexidol and thrombolytic drugs

Authors:

Shchulkin A.V., Chernykh I.V., Abalenikhina Y.V., Gatsanoga M.V., Gradinar M.M., Ananyeva P.D., Yakusheva E.N.

More about the authors

Read: 308 times


To cite this article:

Shchulkin AV, Chernykh IV, Abalenikhina YV, Gatsanoga MV, Gradinar MM, Ananyeva PD, Yakusheva EN. Study of drug-drug interactions between Mexidol and thrombolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(9):139‑144. (In Russ.)
https://doi.org/10.17116/jnevro2025125091139

Recommended articles:
Modern approaches to diagnosis and treatment of syndrome of auto­nomic dysfunction in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):66-75
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Personal characteristics of patients with cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Neuroprotective therapy for age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):152-158
Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90

References:

  1. O’Carroll CB, Brown BL, Freeman WD. Intracerebral hemorrhage: a common yet disproportionately deadly stroke subtype. Mayo Clin Proc. 2021;96(6):1639-1654. https://doi.org/10.1016/j.mayocp.2020.10.034
  2. Ischemic stroke and transient ischemic attack. Clinical guidelines 2024. Ministry of Health of the Russian Federation. (In Russ.). Link active as of 13.04.2025. https://cr.minzdrav.gov.ru/preview-cr/814_1
  3. Voronina TA, Litvinova SA, Gladysheva NA, et al. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ., In Engl.) https://doi.org/10.17116/jnevro202512505122
  4. Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, et al. Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8-2):49-57. (In Russ.). https://doi.org/10.17116/jnevro202012008249
  5. Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, et al. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. S.S. Korsakov Journal of Neurology and Psychiatry. 2006;106(12-2):47-54. (In Russ.).
  6. Voznyuk IA, Kolomentsev SV, Morozova EM. The impact of therapy with Mexidol on neurological deficit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12-2):49-60. (In Russ.). https://doi.org/10.17116/jnevro202312312249
  7. Acheampong P, Ford GA. Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin Drug Metab Toxicol. 2012;8(2):271-281.  https://doi.org/10.1517/17425255.2012.652615
  8. Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clin Pharmacokinet. 2002;41:1229-1245. https://doi.org/10.2165/00003088-200241150-00001
  9. Russian Federation Patent for Invention No. 2 649 760 C1.04.04.2018. Markin S.P., Semenov M.P., Semenov A.M. Method for the Treatment of Acute Myocardial Infarction with ST-Segment Elevation Complicated by Cardiogenic Shock. (In Russ.). Link active as of 13.04.2025. https://elibrary.ru/download/elibrary_38150938_64060647.PDF
  10. Elnager A, Hassan R, Idris Z, et al. Fibrinolytic activity and dose-dependent effect of incubating human blood clots in caffeic acid phenethyl ester: in vitro assays. Biomed Res Int. 2015;2015:627471. https://doi.org/10.1155/2015/627471
  11. Elnager A, Abdullah WZ, Hassan R, et al. In vitro whole blood clot lysis for fibrinolytic activity study using d-dimer and confocal microscopy. Adv Hematol. 2014;2014:814684. https://doi.org/10.1155/2014/814684
  12. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;CD000213. https://doi.org/10.1002/14651858.CD000213.pub3
  13. Gusev EI, Martynov MY, Nikonov AA, et al; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset In Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721-728.  https://doi.org/10.1016/S1474-4422(21)00210-6
  14. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal. 2023;8(1):8-54.  https://doi.org/10.1177/23969873221150022
  15. Seifried E, Tanswell P, Ellbrück D, et al. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost. 1989;61(3):497-501. 
  16. Modi NB, Fox NL, Clow FW, et al. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000;40(5):508-515.  https://doi.org/10.1177/00912700022009125
  17. Vyshlov EV, Alekseeva YaV, Gerasimec EA, et al. Eksperimental’nye i klinicheskie issledovaniya stafilokinazy i Fortelyzina®. Kardiologiya: Novosti. Mneniya. Obuchenie. 2017;2(13):57-61. (In Russ.). https://doi.org/10.24411/2309-1908-2017-00026

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.